takeda pharmaceutical co ltd
(4502:Tokyo Stock Exchange)

Executive Profile*

Background*

Dr. Stephen W. Kaldor serves as Acting Chief Executive Officer Quanticel Pharmaceuticals, Inc. Dr. Kaldor serves as an Advisor of Achaogen, Inc. He is also a Venture Partner at Versant Ventures. e also serves as an Advisor at Thomas, McNerney & Partners and advises on drug discovery. He was a Venture Partner at Versant Ventures. He gained over 12 years of research and development, drug discovery and development experience at Eli Lilly and Company both as a Researcher ... and Director. He served as the Chief Executive Officer and President of Ambrx, Inc. from July 2007 to 2010, and helped mature its drug portfolio and platform through deals with Pfizer, Merck, Lilly, and Merck-Serono. Dr. Kaldor served as the President of Takeda San Diego Inc at Takeda Pharmaceutical Company Limited from 2002 to September 2007. He served as Chief Scientific Officer of Takeda San Diego Inc. from 2002 to September 2007. He served at Syrrx as its Chief Scientific Officer since 2002. From 2000 to 2002, he served as Lilly's Director of Global Chemical Process Research and Development where he managed a group of 270 researchers located both in the United States and Europe supporting activities spanning from late phase lead optimization through Phase I-III clinical trials. He serves as a Director of Takeda San Diego Inc. He has been a Director of Furiex Pharmaceuticals, Inc. since December 10, 2010. Dr. Kaldor served as a Director of Amira Pharmaceuticals, Inc. from April 2008 to 2011. He served as an Executive Director of Ambrx, Inc. He served as Director of Chemistry Research Technologies at Lilly from 1998 to 1999. He served as Director of Anaphore, Inc from 2008 to 2011. He is an Associate Editor of the Journal of Combinatorial Chemistry (ACS) and serves on the Editorial Advisory Boards of three other drug discovery journals. He serves as Member of Scientific Advisor of Crown Bioscience, Inc. Dr. Kaldor has authored 30 publications in peer reviewed journals, has delivered more than 50 invited lectures, and is a co-inventor on 20 issued US patents. He is the co-inventor of multiple compounds that have advanced into the clinic including ViraceptTM, and NesinaTM, and LY334370. He is a chemist by training. He received a Ph.D. in Organic Chemistry in 1989 under the direction of Professor David A. Evans at Harvard University and a B.A., B.S. in Chemistry, magna cum laude, from Columbia University in 1984.

Report Data Issue

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup

Recently Viewed
4502:JP	¥4,745.00 JPY	-55.00

COMPETITOR COMPENSATION